Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer

doi:10.1056/NEJMoa011954

Volume 346:92-98		January 10, 2002		Number 2

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Joan H. Schiller, M.D., David Harrington, Ph.D., Chandra P. Belani, M.D., Corey Langer, M.D., Alan Sandler, M.D., James Krook, M.D., Junming Zhu, Ph.D., David H. Johnson, M.D., for the Eastern Cooperative Oncology Group

Full Text

PDF

PDA Full Text

PowerPoint Slide Set

Editorial
by Carney, D. N.

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

ABSTRACT

Background We conducted a randomized study to determine whetherany of three chemotherapy regimens was superior to cisplatinand paclitaxel in patients with advanced non–small-celllung cancer.

Methods A total of 1207 patients with advanced non–small-celllung cancer were randomly assigned to a reference regimen ofcisplatin and paclitaxel or to one of three experimental regimens:cisplatin and gemcitabine, cisplatin and docetaxel, or carboplatinand paclitaxel.

Results The response rate for all 1155 eligible patients was19 percent, with a median survival of 7.9 months (95 percentconfidence interval, 7.3 to 8.5), a 1-year survival rate of33 percent (95 percent confidence interval, 30 to 36 percent),and a 2-year survival rate of 11 percent (95 percent confidenceinterval, 8 to 12 percent). The response rate and survival didnot differ significantly between patients assigned to receivecisplatin and paclitaxel and those assigned to receive any ofthe three experimental regimens. Treatment with cisplatin andgemcitabine was associated with a significantly longer timeto the progression of disease than was treatment with cisplatinand paclitaxel but was more likely to cause grade 3, 4, or 5renal toxicity (in 9 percent of patients, vs. 3 percent of thosetreated with cisplatin plus paclitaxel). Patients with a performancestatus of 2 had a significantly lower rate of survival thandid those with a performance status of 0 or 1.

Conclusions None of four chemotherapy regimens offered a significantadvantage over the others in the treatment of advanced non–small-celllung cancer.

Source Information

From the University of Wisconsin Hospital and Clinics, Madison (J.H.S.); the Dana–Farber Cancer Institute, Boston (D.H., J.Z.); the University of Pittsburgh Cancer Institute, Pittsburgh (C.P.B.); the Fox Chase Cancer Center, Philadelphia (C.L.); Indiana University, Indianapolis (A.S.); the Duluth Clinic, Duluth, Minn. (J.K.); and Vanderbilt University, Nashville (D.H.J.).

Full Text of this Article

This article has been cited by other articles:

Camerini, A., Valsuani, C., Mazzoni, F., Siclari, O., Puccetti, C., Donati, S., Rondini, M., Tartarelli, G., Puccinelli, P., Di Costanzo, F., Amoroso, D. (2009). Phase II trial of single-agent oral vinorelbine in elderly (>=70 years) patients with advanced non-small-cell lung cancer and poor performance status. Ann Oncol 0: mdp525v1-mdp525 [Abstract] [Full Text]
Lee, S. M., Rudd, R., Woll, P. J., Ottensmeier, C., Gilligan, D., Price, A., Spiro, S., Gower, N., Jitlal, M., Hackshaw, A. (2009). Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer. JCO 27: 5248-5254 [Abstract] [Full Text]
Varella-Garcia, M, Diebold, J, Eberhard, D A, Geenen, K, Hirschmann, A, Kockx, M, Nagelmeier, I, Ruschoff, J, Schmitt, M, Arbogast, S, Cappuzzo, F (2009). EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J. Clin. Pathol. 62: 970-977 [Abstract] [Full Text]
Wang, W., Li, Q., Yamada, T., Matsumoto, K., Matsumoto, I., Oda, M., Watanabe, G., Kayano, Y., Nishioka, Y., Sone, S., Yano, S. (2009). Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clin. Cancer Res. 15: 6630-6638 [Abstract] [Full Text]
Mok, T. S.K., Wu, Y.-L., Yu, C.-J., Zhou, C., Chen, Y.-M., Zhang, L., Ignacio, J., Liao, M., Srimuninnimit, V., Boyer, M. J., Chua-Tan, M., Sriuranpong, V., Sudoyo, A. W., Jin, K., Johnston, M., Chui, W., Lee, J.-S. (2009). Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer. JCO 27: 5080-5087 [Abstract] [Full Text]
Treat, J. A., Gonin, R., Socinski, M. A., Edelman, M. J., Catalano, R. B., Marinucci, D. M., Ansari, R., Gillenwater, H. H., Rowland, K. M., Comis, R. L., Obasaju, C. K., Belani, C. P., for the Alpha Oncology Research Network, (2009). A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol 0: mdp352v1-mdp352 [Abstract] [Full Text]
Sakakibara, T., Inoue, A., Sugawara, S., Maemondo, M., Ishida, T., Usui, K., Abe, T., Kanbe, M., Watanabe, H., Saijo, Y., Nukiwa, T. (2009). Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer. Ann Oncol 0: mdp401v1-mdp401 [Abstract] [Full Text]
West, H., Harpole, D., Travis, W. (2009). Histologic Considerations for Individualized Systemic Therapy Approaches for the Management of Non-small Cell Lung Cancer. Chest 136: 1112-1118 [Abstract] [Full Text]
MOON, Y. W., SOHN, J. H., KIM, Y. T., CHANG, H., JEONG, J. H., LEE, Y. J., CHANG, J., KIM, S. K., JUNG, M., HONG, S., CHOI, S. H., KIM, J.-H. (2009). Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided versus Empirical Chemotherapy in Unresectable Non-small Cell Lung Cancer. Anticancer Res 29: 4243-4249 [Abstract] [Full Text]
KARAPANAGIOTOU, E. M., BOURA, P. G., PAPAMICHALIS, G., KONSTANTINOU, M., SEPSAS, E., CHAMALAKIS, G., SIMSIRIS, P., GKIOZOS, I., SYRIGOS, K. N. (2009). Carboplatin-Pemetrexed Adjuvant Chemotherapy in Resected Non-small Cell Lung Cancer (NSCLC): A Phase II Study. Anticancer Res 29: 4297-4301 [Abstract] [Full Text]
Hiramatsu, A., Iwasaki, Y., Koyama, Y., Tamiya, N., Hosogi, S., Nakanishi, M., Kohno, Y., Ueda, M., Arimoto, T., Marunaka, Y. (2009). Phase II Trial of Weekly Gemcitabine and Split-dose Cisplatin for Advanced Non-small-cell Lung Cancer. Jpn J Clin Oncol 0: hyp111v1-hyp111 [Abstract] [Full Text]
Rudin, C. M., Avila-Tang, E., Harris, C. C., Herman, J. G., Hirsch, F. R., Pao, W., Schwartz, A. G., Vahakangas, K. H., Samet, J. M. (2009). Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications. Clin. Cancer Res. 15: 5646-5661 [Abstract] [Full Text]
Leong, S., Cohen, R. B., Gustafson, D. L., Langer, C. J., Camidge, D. R., Padavic, K., Gore, L., Smith, M., Chow, L. Q., von Mehren, M., O'Bryant, C., Hariharan, S., Diab, S., Fox, N. L., Miceli, R., Eckhardt, S. G. (2009). Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study. JCO 27: 4413-4421 [Abstract] [Full Text]
Blumenschein, G. R. Jr, Gatzemeier, U., Fossella, F., Stewart, D. J., Cupit, L., Cihon, F., O'Leary, J., Reck, M. (2009). Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer. JCO 27: 4274-4280 [Abstract] [Full Text]
Holm, B., Mellemgaard, A., Skov, T., Skov, B. G. (2009). Different Impact of Excision Repair Cross-Complementation Group 1 on Survival in Male and Female Patients With Inoperable Non-Small-Cell Lung Cancer Treated With Carboplatin and Gemcitabine. JCO 27: 4254-4259 [Abstract] [Full Text]
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., Settleman, J., Kobayashi, S., Mark, E. J., Rodig, S. J., Chirieac, L. R., Kwak, E. L., Lynch, T. J., Iafrate, A. J. (2009). Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK. JCO 27: 4247-4253 [Abstract] [Full Text]
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.-J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A., Fukuoka, M. (2009). Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. NEJM 361: 947-957 [Abstract] [Full Text]
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., Insa, A., Massuti, B., Gonzalez-Larriba, J. L., Paz-Ares, L., Bover, I., Garcia-Campelo, R., Moreno, M. A., Catot, S., Rolfo, C., Reguart, N., Palmero, R., Sanchez, J. M., Bastus, R., Mayo, C., Bertran-Alamillo, J., Molina, M. A., Sanchez, J. J., Taron, M., the Spanish Lung Cancer Group, (2009). Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. NEJM 361: 958-967 [Abstract] [Full Text]
Lind, J. S.W., Smit, E. F. (2009). Review: Angiogenesis inhibitors in the treatment of non-small cell lung cancer. Therapeutic Advances in Medical Oncology 1: 95-107 [Abstract]
Bepler, G. (2009). Are We Coming Full Circle for Lung Cancer Screening a Second Time?. Am. J. Respir. Crit. Care Med. 180: 384-385 [Full Text]
Naoki, K., Kunikane, H., Fujii, T., Tsujimura, S., Hida, N., Okamoto, H., Watanabe, K. (2009). Dose-escalating and Pharmacokinetic Study of a Weekly Combination of Paclitaxel and Carboplatin for Inoperable Non-small Cell Lung Cancer: JCOG 9910-DI. Jpn J Clin Oncol 39: 569-575 [Abstract] [Full Text]
Kim, Y. H., Kubota, K., Goto, K., Yoh, K., Niho, S., Ohmatsu, H., Saijo, N., Nishiwaki, Y. (2009). A Phase I Study of Gemcitabine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2. Jpn J Clin Oncol 39: 576-581 [Abstract] [Full Text]
Pao, W., Kris, M. G., Iafrate, A. J., Ladanyi, M., Janne, P. A., Wistuba, I. I., Miake-Lye, R., Herbst, R. S., Carbone, D. P., Johnson, B. E., Lynch, T. J. (2009). Integration of Molecular Profiling into the Lung Cancer Clinic. Clin. Cancer Res. 15: 5317-5322 [Abstract] [Full Text]
Cohen, M. H., Justice, R., Pazdur, R. (2009). Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer. The Oncologist 14: 930-935 [Abstract] [Full Text]
Takano, A., Ishikawa, N., Nishino, R., Masuda, K., Yasui, W., Inai, K., Nishimura, H., Ito, H., Nakayama, H., Miyagi, Y., Tsuchiya, E., Kohno, N., Nakamura, Y., Daigo, Y. (2009). Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer. Cancer Res. 69: 6694-6703 [Abstract] [Full Text]
Horn, L., Sandler, A. (2009). Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer. Clin. Cancer Res. 15: 5040-5048 [Abstract] [Full Text]
Patel, J. D., Hensing, T. A., Rademaker, A., Hart, E. M., Blum, M. G., Milton, D. T., Bonomi, P. D. (2009). Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer. JCO 27: 3284-3289 [Abstract] [Full Text]
Gronberg, B. H., Bremnes, R. M., Flotten, O., Amundsen, T., Brunsvig, P. Fr., Hjelde, H. H., Kaasa, S., von Plessen, C., Stornes, F., Tollali, T., Wammer, F., Aasebo, U., Sundstrom, S. (2009). Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer. JCO 27: 3217-3224 [Abstract] [Full Text]
Tan, E. H., Rolski, J., Grodzki, T., Schneider, C. P., Gatzemeier, U., Zatloukal, P., Aitini, E., Carteni, G., Riska, H., Tsai, Y. H., Abratt, R. (2009). Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 20: 1249-1256 [Abstract] [Full Text]
GARASSINO, M. C., BORGONOVO, K., ROSSI, A., MANCUSO, A., MARTELLI, O., TINAZZI, A., DI COSIMO, S., LA VERDE, N., SBURLATI, P., BIANCHI, C., FARINA, G., TORRI, V. (2009). Biological and Clinical Features in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-analysis. Anticancer Res 29: 2691-2701 [Abstract] [Full Text]
YAMASHITA, S.-I., CHUJO, M., MOROGA, T., ANAMI, K., TOKUISHI, K., MIYAWAKI, M., KAWANO, Y., TAKENO, S., YAMAMOTO, S., KAWAHARA, K. (2009). DYRK2 Expression May be a Predictive Marker for Chemotherapy in Non-small Cell Lung Cancer. Anticancer Res 29: 2753-2757 [Abstract] [Full Text]
Rossi, G., Pelosi, G., Graziano, P., Barbareschi, M., Papotti, M. (2009). Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non--Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments. INT J SURG PATHOL 17: 206-218 [Abstract]
Steger, V., Walles, T., Kosan, B., Walker, T., Kyriss, T., Veit, S., Dippon, J., Friedel, G. (2009). Trimodal Therapy for Histologically Proven N2/3 Non-Small Cell Lung Cancer: Mid-Term Results and Indicators for Survival.. Ann. Thorac. Surg. 87: 1676-1683 [Abstract] [Full Text]
Socinski, M. A., Saleh, M. N., Trent, D. F., Dobbs, T. W., Zehngebot, L. M., Levine, M. A., Bordoni, R., Stella, P. J. (2009). A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann Oncol 20: 1068-1073 [Abstract] [Full Text]
RICE, S. D., BUSH, J. E., BROWER, S. L. (2009). Assessment of Erlotinib in Chemoresponse Assay. Anticancer Res 29: 1993-1997 [Abstract] [Full Text]
Papadaki, C., Mavroudis, D., Trypaki, M., Koutsopoulos, A., Stathopoulos, E., Hatzidaki, D., Tsakalaki, E., Georgoulias, V., Souglakos, J. (2009). Tumoral Expression of TXR1 and TSP1 Predicts Overall Survival of Patients with Lung Adenocarcinoma Treated with First-line Docetaxel-Gemcitabine Regimen. Clin. Cancer Res. 15: 3827-3833 [Abstract] [Full Text]
Natale, R. B., Bodkin, D., Govindan, R., Sleckman, B. G., Rizvi, N. A., Capo, A., Germonpre, P., Eberhardt, W. E.E., Stockman, P. K., Kennedy, S. J., Ranson, M. (2009). Vandetanib Versus Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study. JCO 27: 2523-2529 [Abstract] [Full Text]
Feng, J., Sun, X., Sun, N., Qin, S., Li, F., Cheng, H., Chen, B., Cao, Y., Ma, J., Cheng, L., Lu, Z., Ji, J., Zhou, Y. (2009). XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim Biophys Sin 41: 429-435 [Abstract] [Full Text]
Goss, G., Ferry, D., Wierzbicki, R., Laurie, S. A., Thompson, J., Biesma, B., Hirsch, F. R., Varella-Garcia, M., Duffield, E., Ataman, O. U., Zarenda, M., Armour, A. A. (2009). Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer and Poor Performance Status. JCO 27: 2253-2260 [Abstract] [Full Text]
West, H. L., Wakelee, H. A., Perry, M. C., Belt, R. J., Chen, R., Obasaju, C. (2009). Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. Ann Oncol 20: 850-856 [Abstract] [Full Text]
HIROSE, T., SUGIYAMA, T., KUSUMOTO, S., SHIRAI, T., NAKASHIMA, M., YAMAOKA, T., OKUDA, K., OGURA, K., OHNISHI, T., OHMORI, T., ADACHI, M. (2009). Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer. Anticancer Res 29: 1733-1738 [Abstract] [Full Text]
Grossi, F., Aita, M., Defferrari, C., Rosetti, F., Brianti, A., Fasola, G., Vinante, O., Pronzato, P., Pappagallo, G. (2009). Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach. The Oncologist 14: 497-510 [Abstract] [Full Text]
Horn, L., Sandler, A. B. (2009). Angiogenesis in the Treatment of Non-Small Cell Lung Cancer. Proc Am Thorac Soc 6: 206-217 [Abstract] [Full Text]
Stinchcombe, T. E., Socinski, M. A. (2009). Current Treatments for Advanced Stage Non-Small Cell Lung Cancer. Proc Am Thorac Soc 6: 233-241 [Abstract] [Full Text]
Kuang, Y., Rogers, A., Yeap, B. Y., Wang, L., Makrigiorgos, M., Vetrand, K., Thiede, S., Distel, R. J., Janne, P. A. (2009). Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer. Clin. Cancer Res. 15: 2630-2636 [Abstract] [Full Text]
Sculier, J-P., Moro-Sibilot, D. (2009). First- and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J 33: 915-930 [Abstract] [Full Text]
Sun, Q., Liu, C., Zhong, H., Zhong, B., Xu, H., Shen, W., Wang, D. (2009). Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer. Jpn J Clin Oncol 39: 237-243 [Abstract] [Full Text]
Barros Costa, R. L. (2009). Review Article: Targeted Therapy: Comprehensive Review. AM J HOSP PALLIAT CARE 26: 137-146 [Abstract]
Allen-Auerbach, M., Weber, W. A. (2009). Measuring Response with FDG-PET: Methodological Aspects. The Oncologist 14: 369-377 [Abstract] [Full Text]
Hsu, D. S., Acharya, C. R., Balakumaran, B. S., Riedel, R. F., Kim, M. K., Stevenson, M., Tuchman, S., Mukherjee, S., Barry, W., Dressman, H. K., Nevins, J. R., Powers, S., Mu, D., Potti, A. (2009). Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc. Natl. Acad. Sci. USA 106: 5312-5317 [Abstract] [Full Text]
Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., Ando, M., Yamazaki, K., Saijo, Y., Gemma, A., Miyazawa, H., Tanaka, T., Ikebuchi, K., Nukiwa, T., Morita, S., Hagiwara, K. (2009). First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy. JCO 27: 1394-1400 [Abstract] [Full Text]
Langer, C. J. (2009). The "Lazarus Response" in Treatment-Naive, Poor Performance Status Patients With Non-Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutation. JCO 27: 1350-1354 [Full Text]
Yung, T. K.F., Chan, K.C. A., Mok, T. S.K., Tong, J., To, K.-F., Lo, Y.M. D. (2009). Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non-Small Cell Lung Cancer Patients. Clin. Cancer Res. 15: 2076-2084 [Abstract] [Full Text]
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., Manegold, C. (2009). Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL. JCO 27: 1227-1234 [Abstract] [Full Text]
Motohashi, S., Nagato, K., Kunii, N., Yamamoto, H., Yamasaki, K., Okita, K., Hanaoka, H., Shimizu, N., Suzuki, M., Yoshino, I., Taniguchi, M., Fujisawa, T., Nakayama, T. (2009). A Phase I-II Study of {alpha}-Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured Peripheral Blood Mononuclear Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer. J. Immunol. 182: 2492-2501 [Abstract] [Full Text]
Hsieh, W.-C., Cheng, Y.-W., Lin, C.-J., Chou, M.-C., Chen, C.-Y., Lee, H. (2009). Prognostic Significance of X-ray Cross-complementing Group 1 T-77C Polymorphism in Resected Non-small Cell Lung Cancer. Jpn J Clin Oncol 39: 81-85 [Abstract] [Full Text]
Fidias, P. M., Dakhil, S. R., Lyss, A. P., Loesch, D. M., Waterhouse, D. M., Bromund, J. L., Chen, R., Hristova-Kazmierski, M., Treat, J., Obasaju, C. K., Marciniak, M., Gill, J., Schiller, J. H. (2009). Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer. JCO 27: 591-598 [Abstract] [Full Text]
Crabb, S. J., Patsios, D., Sauerbrei, E., Ellis, P. M., Arnold, A., Goss, G., Leighl, N. B., Shepherd, F. A., Powers, J., Seymour, L., Laurie, S. A. (2009). Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non-Small-Cell Lung Cancer. JCO 27: 404-410 [Abstract] [Full Text]
Alberts, W. M. (2009). Lung Cancer. ACCP Pulmonary Med Brd Rev 25: 39-62 [Full Text]
Extermann, M., Muss, H. B. (2009). Conducting Clinical Trials for Patients Who Are Frail or Elderly. Am Soc Clin Oncol Ed Book 2009: 289-293 [Abstract] [Full Text]
Kim, H.-T., Lee, J.-E., Shin, E.-S., Yoo, Y.-K., Cho, J.-H., Yun, M.-H., Kim, Y.-H., Kim, S.-K., Kim, H.-J., Jang, T.-W., Kwak, S.-M., Kim, C.-S., Ryu, J.-S. (2008). Effect of BRCA1 Haplotype on Survival of Non-Small-Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. JCO 26: 5972-5979 [Abstract] [Full Text]
Soda, M., Takada, S., Takeuchi, K., Choi, Y. L., Enomoto, M., Ueno, T., Haruta, H., Hamada, T., Yamashita, Y., Ishikawa, Y., Sugiyama, Y., Mano, H. (2008). A mouse model for EML4-ALK-positive lung cancer. Proc. Natl. Acad. Sci. USA 105: 19893-19897 [Abstract] [Full Text]
Scagliotti, G. V., Sugarman, K. P. (2008). In Reply. JCO 26: 5651-5652 [Full Text]
Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., Ogino, H., Kakiuchi, S., Hanibuchi, M., Nishioka, Y., Uehara, H., Mitsudomi, T., Yatabe, Y., Nakamura, T., Sone, S. (2008). Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations. Cancer Res. 68: 9479-9487 [Abstract] [Full Text]
Strauss, G. M., Herndon, J. E. II, Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Harpole, D. H., Gillenwater, H. H., Watson, D. M., Sugarbaker, D. J., Schilsky, R. L., Vokes, E. E., Green, M. R. (2008). Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. JCO 26: 5043-5051 [Abstract] [Full Text]
Hernandez, A. M., Toledo, D., Martinez, D., Grinan, T., Brito, V., Macias, A., Alfonso, S., Rondon, T., Suarez, E., Vazquez, A. M., Perez, R. (2008). Characterization of the Antibody Response against NeuGcGM3 Ganglioside Elicited in Non-Small Cell Lung Cancer Patients Immunized with an Anti-Idiotype Antibody. J. Immunol. 181: 6625-6634 [Abstract] [Full Text]
Ko, J.-C., Hong, J.-H., Wang, L.-H., Cheng, C.-M., Ciou, S.-C., Lin, S.-T., Jheng, M.-Y., Lin, Y.-W. (2008). Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells. Molecular Cancer Therapeutics 7: 3632-3641 [Abstract] [Full Text]
de Langen, A. J., Lubberink, M., Boellaard, R., Spreeuwenberg, M. D., Smit, E. F., Hoekstra, O. S., Lammertsma, A. A. (2008). Reproducibility of Tumor Perfusion Measurements Using 15O-Labeled Water and PET. JNM 49: 1763-1768 [Abstract] [Full Text]
Chin, T. M., Quinlan, M. P., Singh, A., Sequist, L. V., Lynch, T. J., Haber, D. A., Sharma, S. V., Settleman, J. (2008). Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment. Clin. Cancer Res. 14: 6867-6876 [Abstract] [Full Text]
Costa, D. B., Nguyen, K.-S. H., Cho, B. C., Sequist, L. V., Jackman, D. M., Riely, G. J., Yeap, B. Y., Halmos, B., Kim, J. H., Janne, P. A., Huberman, M. S., Pao, W., Tenen, D. G., Kobayashi, S. (2008). Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib. Clin. Cancer Res. 14: 7060-7067 [Abstract] [Full Text]
Berhoune, M., Banu, E., Scotte, F., Prognon, P., Oudard, S., Bonan, B. (2008). Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer. The Annals of Pharmacotherapy 42: 1640-1652 [Abstract] [Full Text]
Herbst, R. S., Sandler, A. (2008). Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC. The Oncologist 13: 1166-1176 [Abstract] [Full Text]
Janne, P. A. (2008). Gefitinib First or Gefitinib Second: Is Timing Everything in the Treatment of EGFR Mutant Non-Small Cell Lung Cancer?. Am. J. Respir. Crit. Care Med. 178: 783-785 [Full Text]
von Plessen, C, Strand, T-E, Wentzel-Larsen, T, Omenaas, E, Wilking, N, Sundstrom, S, Sorenson, S (2008). Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study. Thorax 63: 866-871 [Abstract] [Full Text]
Field, J. K. (2008). Lung Cancer Risk Models Come of Age. Cancer Prevention Research 1: 226-228 [Full Text]
Kawata, E., Ashihara, E., Kimura, S., Takenaka, K., Sato, K., Tanaka, R., Yokota, A., Kamitsuji, Y., Takeuchi, M., Kuroda, J., Tanaka, F., Yoshikawa, T., Maekawa, T. (2008). Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Molecular Cancer Therapeutics 7: 2904-2912 [Abstract] [Full Text]
Stinchcombe, T. E., Socinski, M. A. (2008). Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?. The Oncologist 13: 933-944 [Abstract] [Full Text]
Manegold, C., Gravenor, D., Woytowitz, D., Mezger, J., Hirsh, V., Albert, G., Al-Adhami, M., Readett, D., Krieg, A. M., Leichman, C. G. (2008). Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non-Small-Cell Lung Cancer. JCO 26: 3979-3986 [Abstract] [Full Text]
Okamoto, I., Nishimura, T., Miyazaki, M., Yoshioka, H., Kubo, A., Takeda, K., Ebi, N., Sugawara, S., Katakami, N., Fukuoka, M., Nakagawa, K. (2008). Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non-Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505. Clin. Cancer Res. 14: 5250-5254 [Abstract] [Full Text]
Flaherty, K. T., Schiller, J., Schuchter, L. M., Liu, G., Tuveson, D. A., Redlinger, M., Lathia, C., Xia, C., Petrenciuc, O., Hingorani, S. R., Jacobetz, M. A., Van Belle, P. A., Elder, D., Brose, M. S., Weber, B. L., Albertini, M. R., O'Dwyer, P. J. (2008). A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel. Clin. Cancer Res. 14: 4836-4842 [Abstract] [Full Text]
Chee, K. G., Nguyen, D. V., Brown, M., Gandara, D. R., Wun, T., Lara, P. N. Jr (2008). Positron Emission Tomography and Improved Survival in Patients With Lung Cancer: The Will Rogers Phenomenon Revisited. Arch Intern Med 168: 1541-1549 [Abstract] [Full Text]
Schiller, J. H. (2008). Noninvasive Monitoring of Tumors. NEJM 359: 418-420 [Full Text]
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., Lee, J. S., Mellemgaard, A., Park, K., Patil, S., Rolski, J., Goksel, T., de Marinis, F., Simms, L., Sugarman, K. P., Gandara, D. (2008). Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. JCO 26: 3543-3551 [Abstract] [Full Text]
Ko, J.-C., Ciou, S.-C., Cheng, C.-M., Wang, L.-H., Hong, J.-H., Jheng, M.-Y., Ling, S.-T., Lin, Y.-W. (2008). Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. Carcinogenesis 29: 1448-1458 [Abstract] [Full Text]
Miyanaga, A., Gemma, A., Noro, R., Kataoka, K., Matsuda, K., Nara, M., Okano, T., Seike, M., Yoshimura, A., Kawakami, A., Uesaka, H., Nakae, H., Kudoh, S. (2008). Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Molecular Cancer Therapeutics 7: 1923-1930 [Abstract] [Full Text]
Hoskin, P. (2008). Opioids in context: relieving the pain of cancer. The role of comprehensive cancer management. Palliat Med 22: 303-309 [Abstract]
Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Janne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., Kuhlmann, G. L., Han, M., Goldberg, J. S., Settleman, J., Iafrate, A. J., Engelman, J. A., Haber, D. A., Johnson, B. E., Lynch, T. J. (2008). First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations. JCO 26: 2442-2449 [Abstract] [Full Text]

Comments and questions? Please contact us.